Sign In


Tanios Bekaii-Saab MD

Tanios Bekaii-Saab MD
Assoc ProfessorCollege of Medicinetanios.bekaii-saab@osumc.edu
B421 Starling Loving Hall 320 W 10th Avenue Columbus OH 43210
Phone:614-293-9863Fax: 614-293-4372
  • Experimental Therapeutics

Current Publications

  • Mortazavi A, Ling Y, Martin LK, Wei L, Phelps MA, Liu Z, Harper EJ, Ivy SP, Wu X, Zhou BS, Liu X, Deam D, Monk JP, Hicks WJ, Yen Y, Otterson GA, Grever MR, Bekaii-Saab TA phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.Invest New Drugs 31(3) 685-95 6/1/2013
  • Mace TA, Ameen Z, Collins A, Wojcik SE, Mair M, Young GS, Fuchs JR, Eubank TD, Frankel WL, Bekaii-Saab T, Bloomston M, Lesinski GBPancreatic Cancer-Associated Stellate Cells Promote Differentiation of Myeloid-Derived Suppressor Cells in a STAT3-Dependent Manner.Cancer Res 73(10) 3007-18 5/15/2013
  • Brar S, Law C, McLeod R, Helyer L, Swallow C, Paszat L, Seevaratnam R, Cardoso R, Dixon M, Mahar A, Lourenco LG, Yohanathan L, Bocicariu A, Bekaii-Saab T, Chau I, Church N, Coit D, Crane CH, Earle C, Mansfield P, Marcon N, Miner T, Noh SH, Porter G, Posner MC, Prachand V, Sano T, van de Velde C, Wong S, Coburn NDefining Surgical Quality in Gastric Cancer: A RAND/UCLA Appropriateness Study.J Am Coll Surg in press 5/8/2013
  • Benson AB 3rd, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W Jr, Sofocleous CT, Venook AP, Willett CG, Gregory KM, Freedman-Cass DALocalized Colon Cancer, Version 3.2013.J Natl Compr Canc Netw 11(5) 519-528 5/1/2013
  • Rubinson DA, Hochster HS, Ryan DP, Wolpin BM, McCleary NJ, Abrams TA, Chan JA, Iqbal S, Lenz HJ, Lim D, Rose J, Bekaii-Saab T, Chen HX, Fuchs CS, Ng KMulti-drug inhibition of the HER pathway in metastatic colorectal cancer: Results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients.Invest New Drugs in press 4/9/2013
  • Patnaik A, Papadopoulos KP, Tolcher AW, Beeram M, Urien S, Schaaf LJ, Tahiri S, Bekaii-Saab T, Lokiec FM, Rezaï K, Buchbinder APhase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer.Cancer Chemother Pharmacol in press 3/30/2013
  • Coburn N, Seevaratnam R, Paszat L, Helyer L, Law C, Swallow C, Cardosa R, Mahar A, Lourenco LG, Dixon M, Bekaii-Saab T, Chau I, Church N, Coit D, Crane CH, Earle C, Mansfield P, Marcon N, Miner T, Noh SH, Porter G, Posner MC, Prachand V, Sano T, van de Velde C, Wong S, McLeod ROptimal Management of Gastric Cancer: Results From an International RAND/UCLA Expert Panel.Ann Surg in press 3/8/2013
  • Wu C, Fernandez SA, Criswell T, Chidiac TA, Guttridge D, Villalona-Calero M, Bekaii-Saab TSDisrupting Cytokine Signaling in Pancreatic Cancer: A Phase I/II Study of Etanercept in Combination With Gemcitabine in Patients With Advanced Disease.Pancreas in press 3/4/2013
  • Martin LK, Bekaii-Saab TOptimizing neoadjuvant therapy for rectal cancer with oxaliplatin.J Natl Compr Canc Netw 11(3) 298-307; quiz 307 3/1/2013
  • Benson AB 3rd, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W Jr, Sofocleous CT, Venook AP, Willett CG, Gregory KM, Freedman-Cass DAMetastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines.J Natl Compr Canc Netw 11(2) 141-52; quiz 152 2/1/2013
  • Bertino EM, Bekaii-Saab T, Fernandez S, Diasio RB, Karim NA, Otterson GA, Villalona-Calero MAA phase II study of modulated-capecitabine and docetaxel in chemonaive patients with advanced non-small cell lung cancer (NSCLC).Lung Cancer 79(1) 27-32 1/1/2013
  • Rose JS, Serna DS, Martin LK, Li X, Weatherby LM, Abdel-Misih S, Zhao W, Bekaii-Saab TInfluence of KRAS mutation status in metachronous and synchronous metastatic colorectal adenocarcinoma.Cancer 118(24) 6243-52 12/15/2012
  • Benson AB 3rd, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fuchs CS, Grem JL, Hunt S, Leong LA, Lin E, Martin MG, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W Jr, Sofocleous CT, Venook AP, Willett CG, Freedman-Cass DA, Gregory KMRectal cancer.J Natl Compr Canc Netw 10(12) 1528-64 12/1/2012
  • Martin LK, Wei L, Trolli E, Bekaii-Saab TElevated baseline CA19-9 levels correlate with adverse prognosis in patients with early- or advanced-stage pancreas cancer.Med Oncol 29(5) 3101-7 12/1/2012
  • Martin LK, Grecula J, Jia G, Wei L, Yang X, Otterson GA, Wu X, Harper E, Kefauver C, Zhou BS, Yen Y, Bloomston M, Knopp M, Ivy SP, Grever M, Bekaii-Saab TA dose escalation and pharmacodynamic study of triapine and radiation in patients with locally advanced pancreas cancer.Int J Radiat Oncol Biol Phys 84(4) e475-81 11/15/2012
  • Martin LK, Li X, Kleiber B, Ellison EC, Bloomston M, Zalupski M, Bekaii-Saab TSVEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA.Ann Oncol 23(11) 2812-20 11/1/2012
  • Martin LK, Otterson GA, Bekaii-Saab TPhotodynamic therapy (PDT) may provide effective palliation in the treatment of primary tracheal carcinoma: a small case series.Photomed Laser Surg 30(11) 668-71 11/1/2012
  • Martin LK, Cucci A, Wei L, Rose J, Blazer M, Schmidt C, Khabiri H, Bloomston PM, Bekaii-Saab TYttrium-90 radioembolization as salvage therapy for colorectal cancer with liver metastases.Clin Colorectal Cancer 11(3) 195-9 9/1/2012
  • Ramaswamy B, Phelps MA, Baiocchi R, Bekaii-Saab T, Ni W, Lai JP, Wolfson A, Lustberg ME, Wei L, Wilkins D, Campbell A, Arbogast D, Doyle A, Byrd JC, Grever MR, Shah MHA dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors.Invest New Drugs 30(2) 629-38 4/1/2012
  • Peck J, Wei L, Zalupski M, O'Neil B, Villalona MA, Bekaii-Saab THER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib.Oncology 82(3) 175-9 1/1/2012
  • Martin LK, Bekaii-Saab TManagement of venous thromboembolism in patients with advanced gastrointestinal cancers: what is the role of novel oral anticoagulants?Thrombosis 2012 758385 1/1/2012
  • Bendell JC, Bekaii-Saab TS, Cohn AL, Hurwitz HI, Kozloff M, Tezcan H, Roach N, Mun Y, Fish S, Flick ED, Dalal D, Grothey ATreatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study.Oncologist 17(12) 1486-95 1/1/2012
  • Serna DS, Bekaii-Saab T, Kraut EHA phase I study of topotecan and gemcitabine in advanced solid tumors.Invest New Drugs 29(6) 1390-4 12/1/2011
  • Mundy-Bosse BL, Young GS, Bauer T, Binkley E, Bloomston M, Bill MA, Bekaii-Saab T, Carson WE 3rd, Lesinski GBDistinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4⁺ T cells from patients with GI malignancy.Cancer Immunol Immunother 60(9) 1269-79 9/1/2011
  • O'Neil BH, Goff LW, Kauh JS, Strosberg JR, Bekaii-Saab TS, Lee RM, Kazi A, Moore DT, Learoyd M, Lush RM, Sebti SM, Sullivan DMPhase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma.J Clin Oncol 29(17) 2350-6 6/10/2011
  • Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MAMulti-institutional phase II study of selumetinib in patients with metastatic biliary cancers.J Clin Oncol 29(17) 2357-63 6/10/2011